Moderna, Inc. $MRNA Shares Bought by UniSuper Management Pty Ltd

UniSuper Management Pty Ltd raised its position in Moderna, Inc. (NASDAQ:MRNA) by 9.6% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 55,856 shares of the company’s stock after acquiring an additional 4,903 shares during the quarter. UniSuper Management Pty Ltd’s holdings in Moderna were worth $1,584,000 as of its most recent SEC filing.

Several other institutional investors also recently bought and sold shares of the company. Theleme Partners LLP boosted its position in Moderna by 1.0% in the 4th quarter. Theleme Partners LLP now owns 7,306,861 shares of the company’s stock valued at $303,819,000 after buying an additional 72,028 shares during the period. Invesco Ltd. boosted its position in Moderna by 17.5% in the 1st quarter. Invesco Ltd. now owns 5,883,624 shares of the company’s stock valued at $166,801,000 after buying an additional 877,162 shares during the period. Northern Trust Corp boosted its position in Moderna by 5.4% in the 1st quarter. Northern Trust Corp now owns 3,119,626 shares of the company’s stock valued at $88,441,000 after buying an additional 160,572 shares during the period. Charles Schwab Investment Management Inc. boosted its position in Moderna by 12.2% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 2,629,865 shares of the company’s stock valued at $74,557,000 after buying an additional 285,662 shares during the period. Finally, Voloridge Investment Management LLC boosted its position in Moderna by 335.6% in the 4th quarter. Voloridge Investment Management LLC now owns 2,590,831 shares of the company’s stock valued at $107,727,000 after buying an additional 1,996,003 shares during the period. 75.33% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several equities analysts have commented on the stock. JPMorgan Chase & Co. set a $26.00 price target on shares of Moderna in a research report on Friday, August 1st. William Blair restated a “market perform” rating on shares of Moderna in a research note on Monday, June 2nd. Cowen started coverage on shares of Moderna in a research note on Sunday, July 13th. They set a “hold” rating on the stock. Citigroup started coverage on shares of Moderna in a research note on Friday, August 1st. They set a “neutral” rating and a $40.00 target price on the stock. Finally, Wells Fargo & Company restated an “equal weight” rating on shares of Moderna in a research note on Sunday, July 13th. One equities research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, sixteen have assigned a Hold rating and four have assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $42.88.

Moderna Stock Down 0.7%

Shares of Moderna stock opened at $24.31 on Thursday. The firm has a market capitalization of $9.46 billion, a P/E ratio of -3.23 and a beta of 1.93. Moderna, Inc. has a 52 week low of $23.15 and a 52 week high of $79.88. The firm’s 50 day moving average is $28.58 and its two-hundred day moving average is $28.34.

Moderna (NASDAQ:MRNA) last announced its quarterly earnings results on Friday, August 1st. The company reported ($2.13) EPS for the quarter, beating the consensus estimate of ($2.99) by $0.86. The company had revenue of $142.00 million for the quarter, compared to analyst estimates of $116.26 million. Moderna had a negative net margin of 94.31% and a negative return on equity of 25.96%. The firm’s revenue was down 41.1% on a year-over-year basis. During the same period in the prior year, the firm posted ($3.33) earnings per share. Moderna has set its FY 2025 guidance at EPS. As a group, research analysts expect that Moderna, Inc. will post -9.61 earnings per share for the current fiscal year.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.